Large-cap health care company Johnson & Johnson has moved -0.3% this afternoon, reaching $152.29 per share. In contrast, the average analyst target price for the stock is $179.1.
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company is based in the United States. Johnson & Johnson currently returns an annual dividend yield of 3.0%.
Make Sure to Consider the Following Before Buying Johnson & Johnson:
-
Johnson & Johnson has moved -7.0% over the last year.
-
JNJ has a forward P/E ratio of 14.0 based on its EPS guidance of 10.84.
-
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 55.8%.
-
The company has a price to earnings growth (PEG) ratio of 2.91.
-
Its Price to Book (P/B) ratio is 5.27
Johnson & Johnson Has Irregular Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-16 | 21,194,000 | -3,466,000 | 24,660,000 | -6.42 |
| 2022-02-17 | 23,410,000 | -2,941,000 | 26,351,000 | -0.85 |
| 2021-02-22 | 23,536,000 | -3,042,000 | 26,578,000 | 12.39 |
| 2020-02-18 | 23,416,000 | -233,000 | 23,649,000 | 4.33 |
| 2019-02-20 | 22,201,000 | -467,000 | 22,668,000 | 0.73 |
| 2018-02-21 | 21,056,000 | -1,447,000 | 22,503,000 |
Johnson & Johnson's free cash flows have a decent average of $24.4 Billion over the last 6 years, but they are highly variable since their coefficient of variability is 104706446633.7%. The compounded average growth rate over this period is 0.0%.
